SecBot SecBot
PRESS-RELEASE ·Filed May 13, 2026

ABUS

Arbutus Biopharma Corporation
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The Moderna settlement provides a substantial near-term cash infusion ($178.7M expected in July 2026) and removes a major litigation overhang. Monitor for the contingent $1.3B payment decision and upcoming imdusiran Phase 2b data. The Fast Track designation could accelerate regulatory timelines.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.31
T+0 close · May 13, 2026 · via day close
Latest settled
+7.42%
T+60 · $4.63
Vs SPY
+2.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $4.31entry
  2. T+1 · 6mo ago +0.93%α +0.15% · $4.35
  3. T+5 · 6mo ago −2.55%α −1.39% · $4.20
  4. T+20 · 5mo ago −0.46%α +0.15% · $4.29
  5. T+60 · 3mo ago +7.42%α +2.99% · $4.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in license revenue from the Moderna settlement. Revenue surged to $179.1M from $1.8M YoY, and the company ended the quarter with $95.2M in cash. The stock will move on the magnitude of the settlement cash inflow and the FDA Fast Track designation for imdusiran, though the core business remains pre-revenue.

Key Financial Metrics

EPS
$0.87
est −$0.06 · +1550.0%
Revenue
$179.1M
est $1.5M · +11841.7% · +10055.1% YoY
Rating
strong beat

Key Facts

  • Q1 2026 GAAP diluted EPS $0.87 vs consensus -$0.06 (beat by $0.93)
  • Total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
  • Net income $169.7M vs net loss $24.5M YoY
  • Cash, cash equivalents and marketable securities $95.2M as of March 31, 2026
  • FDA granted Fast Track designation for imdusiran (chronic hepatitis B) in April 2026
  • Moderna settlement includes $950M upfront payment (July 2026) plus up to $1.3B contingent payment
  • Company expects to receive ~$178.7M of the upfront payment in July 2026
  • Operating cash flow used $8.1M in Q1 2026, including restructuring payments

Financial Impact

Q1 revenue of $179.1M (vs $1.8M YoY) driven by $178.7M license revenue; net income of $169.7M vs loss of $24.5M; cash position $95.2M

revenueepscash

Risk Factors

  • Core business remains pre-revenue; ongoing operating cash burn of ~$8M/quarter
  • Contingent $1.3B Moderna payment depends on appellate ruling under 28 U.S.C. §1498
  • Imdusiran clinical and regulatory risk; no guarantee of approval
  • Restructuring and workforce reduction may impact future R&D capabilities

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293879

Track record

25 reports on ABUS

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 5 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026